Review articles cover how pre-MEASURE has impacted clinical decision-making and the interpretation of NPM1 MRD throughout the treatment course of AML. Other manuscripts address the limitations of ...

The company recently announced that its pivotal Phase 2 KOMET-001 trial in relapsed/refractory NPM1-mutated AML met ... and minimal residual disease (MRD) negativity in challenging AML frontline ...

We're preparing to commercialize ziftomenib as a potentially best-in-class menin inhibitor for patients with relapsed and/or refractory NPM1-mutant ... the trials to use MRD-negative CR and ...

Also in the second quarter, we expect to publish the pivotal NPM1 data and believe this could ... the overall response rate was 100% and the MRD negative rate was 95% among 37 efficacy evaluable ...

Early clearance of measurable residual disease (MRD) after induction therapy in patients with acute myeloid leukemia (AML) is associated with significantly better relapse-free survival (RFS ...

General and administrative (G&A) expenses for the fourth quarter of 2024 were $24.1 million, compared to $14.2 million for the fourth quarter of 2023. G&A expenses for the full year 2024 were $77.1 ...

Kura Oncology Inc (NASDAQ:KURA) is poised to submit its first NDA for ziftomenib, a potentially best-in-class menin inhibitor for relapsed/refractory NPM1-mutant ... for the MRD-negative CR ...

The trial will assess MRD-negative complete response and event ... For ziftomenib, we expect to submit an NDA in relapsed/refractory NPM1-mutant AML in Q2, present top-line data for KOMET-001 ...

We're preparing to commercialize ziftomenib as a potentially best-in-class menin inhibitor for patients with relapsed and/or refractory NPM1-mutant AML ... settings by allowing the trials to use ...